Sarepta Therapeutics provided $15m in a series A round for the company, which is advancing University of Florida research.
US-based gene therapy startup AavantiBio launched yesterday with $107m in a series A round to commercialise University of Florida research.
The round featured genetic medicine developer Sarepta Therapeutics, hedge fund sponsor Perceptive Advisors, investment manager RA Capital Management and Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital.
AavantiBio will concentrate on genetic therapeutics for rare diseases and its initial focus is on Friedreich’s Ataxia (FA), an inherited genetic disease that leads to central nervous…
